Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients

被引：28
作者：
Du, J.
Zhang, A. [1 ]
Wang, L. [1 ]
Xuan, J. [1 ]
Yu, L. [1 ]
Che, R. [1 ]
Li, X. [1 ]
Gu, N. [3 ]
Lin, Z. [3 ]
Feng, G. [3 ]
Xing, Q. [1 ]
He, L. [1 ,2 ]
机构：
[1] Chinese Acad Sci, Inst Nutr Sci, SIBS, Shanghai 200031, Peoples R China
[2] Shanghai Jiao Tong Univ, Bio X Ctr, NHGG, Shanghai 200030, Peoples R China
[3] Shanghai Inst Mental Hlth, Shanghai, Peoples R China
来源：
JOURNAL OF PSYCHOPHARMACOLOGY | 2010年 / 24卷 / 07期
基金：
中国国家自然科学基金;
关键词：
9-hydroxyrisperidone; clinical response; CYP3A4; risperidone; schizophrenia; ANTIPSYCHOTIC-DRUGS; METABOLISM; RELAPSE; CYP2D6; PREVENTION; POOR; 2D6;
D O I：
10.1177/0269881109104932
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
In this study, we examined the relationships between plasma concentrations of risperidone and 9-hydroxyrisperidone and polymorphisms of CYP3A4. All 130 schizophrenia patients (45 men, 85 women, age 15-60 years) who met DSM-IV criteria were given risperidone for 8 weeks. Clinical efficacy was determined using the Positive and Negative Syndrome Scale (PANSS). CYP3A4*1G was found to be associated with the change in total PANSS scores (Kruskal-Wallis test, P = 0.021), which was not significant on adjusting for multiple testing. Our study has, for the first time, conducted a genetic association study of the CYP3A4 gene with risperidone response. Further studies on larger groups and on the effects of the longer term risperidone treatment are needed to confirm these results.
引用
收藏
页码：1115 / 1120
页数：6
相关论文
共 28 条
  • [1] A single-nucleotide polymorphism tagging set for human drug metabolism and transport
    Ahmadi, KR
    Weale, ME
    Xue, ZYY
    Soranzo, N
    Yarnall, DP
    Briley, JD
    Maruyama, Y
    Kobayashi, M
    Wood, NW
    Spurr, NK
    Burns, DK
    Roses, AD
    Saunders, AM
    Goldstein, DB
    [J]. NATURE GENETICS, 2005, 37 (01) : 84 - 89
  • [2] A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia
    Csernansky, JG
    Mahmoud, R
    Brenner, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (01) : 16 - 22
  • [3] DEPOT ANTIPSYCHOTIC-DRUGS - PLACE IN THERAPY
    DAVIS, JM
    METALON, L
    WATANABE, MD
    BLAKE, L
    [J]. DRUGS, 1994, 47 (05) : 741 - 773
  • [4] The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation
    de Leon, J
    Susce, MT
    Pan, RM
    Fairchild, M
    Koch, WH
    Wedlund, PJ
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) : 15 - 27
  • [5] The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19
    de Leon, Jose
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (03) : 241 - 245
  • [6] An evaluation of risperidone drug interactions
    DeVane, CL
    Nemeroff, CB
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (04) : 408 - 416
  • [7] Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population
    Du, Jing
    Xing, Qinghe
    Xu, Lingyun
    Xu, Mingsheng
    Shu, Anli
    Shi, Yongyong
    Yu, Lan
    Zhang, Aiping
    Wang, Lei
    Wang, Hongsheng
    Li, Xingwang
    Feng, Guoyin
    He, Lin
    [J]. PHARMACOGENOMICS, 2006, 7 (06) : 831 - 841
  • [8] Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4
    Fang, J
    Bourin, M
    Baker, GB
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (02) : 147 - 151
  • [9] G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences
    Faul, Franz
    Erdfelder, Edgar
    Lang, Albert-Georg
    Buchner, Axel
    [J]. BEHAVIOR RESEARCH METHODS, 2007, 39 (02) : 175 - 191
  • [10] FLAUM M, 1997, DSM 4 SOURCEBOOK
123